S&P 500   4,584.12 (+0.37%)
DOW   36,217.89 (+0.26%)
QQQ   389.12 (+0.47%)
AAPL   193.65 (+0.12%)
MSFT   373.10 (+0.16%)
META   320.77 (+0.78%)
GOOGL   131.45 (+0.35%)
AMZN   146.66 (-0.15%)
TSLA   244.67 (+2.49%)
NVDA   473.06 (+1.59%)
NIO   7.68 (+3.36%)
BABA   72.27 (-0.15%)
AMD   122.09 (+3.13%)
T   16.94 (-1.63%)
F   10.78 (+1.70%)
MU   74.91 (+1.66%)
CGC   0.68 (+1.56%)
GE   122.34 (+1.75%)
DIS   91.10 (+0.34%)
AMC   7.08 (+0.85%)
PFE   29.14 (+0.17%)
PYPL   58.39 (+0.81%)
XOM   100.17 (-0.27%)
S&P 500   4,584.12 (+0.37%)
DOW   36,217.89 (+0.26%)
QQQ   389.12 (+0.47%)
AAPL   193.65 (+0.12%)
MSFT   373.10 (+0.16%)
META   320.77 (+0.78%)
GOOGL   131.45 (+0.35%)
AMZN   146.66 (-0.15%)
TSLA   244.67 (+2.49%)
NVDA   473.06 (+1.59%)
NIO   7.68 (+3.36%)
BABA   72.27 (-0.15%)
AMD   122.09 (+3.13%)
T   16.94 (-1.63%)
F   10.78 (+1.70%)
MU   74.91 (+1.66%)
CGC   0.68 (+1.56%)
GE   122.34 (+1.75%)
DIS   91.10 (+0.34%)
AMC   7.08 (+0.85%)
PFE   29.14 (+0.17%)
PYPL   58.39 (+0.81%)
XOM   100.17 (-0.27%)
S&P 500   4,584.12 (+0.37%)
DOW   36,217.89 (+0.26%)
QQQ   389.12 (+0.47%)
AAPL   193.65 (+0.12%)
MSFT   373.10 (+0.16%)
META   320.77 (+0.78%)
GOOGL   131.45 (+0.35%)
AMZN   146.66 (-0.15%)
TSLA   244.67 (+2.49%)
NVDA   473.06 (+1.59%)
NIO   7.68 (+3.36%)
BABA   72.27 (-0.15%)
AMD   122.09 (+3.13%)
T   16.94 (-1.63%)
F   10.78 (+1.70%)
MU   74.91 (+1.66%)
CGC   0.68 (+1.56%)
GE   122.34 (+1.75%)
DIS   91.10 (+0.34%)
AMC   7.08 (+0.85%)
PFE   29.14 (+0.17%)
PYPL   58.39 (+0.81%)
XOM   100.17 (-0.27%)
S&P 500   4,584.12 (+0.37%)
DOW   36,217.89 (+0.26%)
QQQ   389.12 (+0.47%)
AAPL   193.65 (+0.12%)
MSFT   373.10 (+0.16%)
META   320.77 (+0.78%)
GOOGL   131.45 (+0.35%)
AMZN   146.66 (-0.15%)
TSLA   244.67 (+2.49%)
NVDA   473.06 (+1.59%)
NIO   7.68 (+3.36%)
BABA   72.27 (-0.15%)
AMD   122.09 (+3.13%)
T   16.94 (-1.63%)
F   10.78 (+1.70%)
MU   74.91 (+1.66%)
CGC   0.68 (+1.56%)
GE   122.34 (+1.75%)
DIS   91.10 (+0.34%)
AMC   7.08 (+0.85%)
PFE   29.14 (+0.17%)
PYPL   58.39 (+0.81%)
XOM   100.17 (-0.27%)

Ingevity Stock Price, News & Analysis (NYSE:NGVT)

$39.22
+0.37 (+0.95%)
(As of 09:32 AM ET)
Compare
Today's Range
$38.87
$39.22
50-Day Range
$37.42
$48.18
52-Week Range
$36.66
$90.81
Volume
3,706 shs
Average Volume
309,765 shs
Market Capitalization
$1.42 billion
P/E Ratio
11.47
Dividend Yield
N/A
Price Target
$50.00

Ingevity MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
28.7% Upside
$50.00 Price Target
Short Interest
Healthy
2.41% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
15.53%
From $3.80 to $4.39 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.43 out of 5 stars

Basic Materials Sector

92nd out of 176 stocks

Chemicals & Allied Products Industry

10th out of 15 stocks


NGVT stock logo

About Ingevity Stock (NYSE:NGVT)

Ingevity Corporation manufactures and sells specialty chemicals and activated carbon materials in North America, the Asia Pacific, Europe, the Middle East, Africa, and South America. It operates through two segments, Performance Materials and Performance Chemicals. The Performance Materials segment engineers, manufactures, and sells hardwood-based and chemically activated carbon products primarily for use in gasoline vapor emission control systems in cars, motorcycles, trucks, and boats. This segment also produces other activated carbon products for use in various applications, including food, water, beverage, and chemical purification. The Performance Chemicals segment comprises of pavement technologies, industrial specialties, and engineered polymers. It manufactures products derived from crude tall oil and lignin extracted from the kraft pulping process, as well as caprolactone monomers and derivatives derived from cyclohexanone and hydrogen peroxide. This segment's products are used in various applications comprising warm mix paving, pavement preservation, pavement reconstruction and recycling, road striping, oil well service additives, oil production, and downstream applications; and adhesives, agrochemical dispersants, lubricants, printing inks, industrial intermediates and oilfield, coatings, resins, elastomers, bioplastics, and medical devices. The company was founded in 1964 and is headquartered in North Charleston, South Carolina.

NGVT Stock Price History

NGVT Stock News Headlines

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Ingevity (NGVT) Declined on Lowering Full-Year Guidance
Ingevity Corp NGVT
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Ingevity's (NGVT) Earnings and Sales Miss Estimates in Q3
Ingevity reports third quarter 2023 financial results
Here's what Wall Street expects from Ingevity's earnings report
Show Some Investing Ingenuity With Ingevity
Loop Capital Downgrades Ingevity (NGVT)
See More Headlines
Receive NGVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ingevity and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/01/2023
Today
12/06/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/26/2024

Industry, Sector and Symbol

Industry
Chemicals & allied products
Sub-Industry
N/A
Previous Symbol
NASDAQ:NGVT
Employees
2,050
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$50.00
High Stock Price Target
$55.00
Low Stock Price Target
$43.00
Potential Upside/Downside
+28.7%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
4 Analysts

Profitability

Net Income
$211.60 million
Pretax Margin
9.60%

Debt

Sales & Book Value

Annual Sales
$1.67 billion
Cash Flow
$8.69 per share
Book Value
$18.68 per share

Miscellaneous

Free Float
35,945,000
Market Cap
$1.41 billion
Optionable
Optionable
Beta
1.82
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. John C. Fortson (Age 56)
    President, CEO & Director
    Comp: $2.57M
  • Ms. Mary Dean Hall (Age 65)
    Executive VP & CFO
    Comp: $1.14M
  • Ms. Stacy Lancaster Cozad (Age 52)
    Executive VP, General Counsel & Secretary
    Comp: $1.05M
  • Mr. Stuart Edward Woodcock Jr.Mr. Stuart Edward Woodcock Jr. (Age 57)
    Executive VP & President of Performance Materials
    Comp: $960.98k
  • Mr. Richard White (Age 60)
    Senior VP & President of Performance Chemicals
    Comp: $854.88k
  • Mr. Phillip John Platt (Age 42)
    VP, Chief Accounting Officer & Business Transformation Lead
  • John E. Nypaver Jr.
    VP of Investor Relations & Treasurer
  • Caroline Monahan
    Director of Communications
  • Ms. Christine Stunyo (Age 44)
    Senior VP & Chief Human Resources Officer
  • Mr. Steve Hulme (Age 54)
    Senior VP & President of Advanced Polymer Technologies














NGVT Stock Analysis - Frequently Asked Questions

Should I buy or sell Ingevity stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ingevity in the last year. There are currently 4 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NGVT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NGVT, but not buy additional shares or sell existing shares.
View NGVT analyst ratings
or view top-rated stocks.

What is Ingevity's stock price target for 2024?

4 analysts have issued 12 month price objectives for Ingevity's shares. Their NGVT share price targets range from $43.00 to $55.00. On average, they anticipate the company's share price to reach $50.00 in the next twelve months. This suggests a possible upside of 28.7% from the stock's current price.
View analysts price targets for NGVT
or view top-rated stocks among Wall Street analysts.

How have NGVT shares performed in 2023?

Ingevity's stock was trading at $70.44 on January 1st, 2023. Since then, NGVT stock has decreased by 44.8% and is now trading at $38.85.
View the best growth stocks for 2023 here
.

When is Ingevity's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024.
View our NGVT earnings forecast
.

How were Ingevity's earnings last quarter?

Ingevity Co. (NYSE:NGVT) issued its earnings results on Wednesday, November, 1st. The company reported $1.21 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.22 by $0.01. The company earned $446 million during the quarter, compared to analysts' expectations of $464.28 million. Ingevity had a net margin of 7.45% and a trailing twelve-month return on equity of 22.18%. The firm's quarterly revenue was down 7.5% compared to the same quarter last year. During the same period in the prior year, the business earned $2.09 earnings per share.

What ETFs hold Ingevity's stock?
What is John Fortson's approval rating as Ingevity's CEO?

2 employees have rated Ingevity Chief Executive Officer John Fortson on Glassdoor.com. John Fortson has an approval rating of 100% among the company's employees. This puts John Fortson in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Ingevity own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ingevity investors own include Pfizer (PFE), AbbVie (ABBV), General Electric (GE), Verizon Communications (VZ), WestRock (WRK), Abbott Laboratories (ABT), Boeing (BA), Costco Wholesale (COST), Dominion Energy (D) and Johnson & Johnson (JNJ).

Who are Ingevity's major shareholders?

Ingevity's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (5.71%), LSV Asset Management (3.86%), Victory Capital Management Inc. (3.25%), Brown Advisory Inc. (2.05%), American Century Companies Inc. (1.36%) and Charles Schwab Investment Management Inc. (1.21%). Insiders that own company stock include Erik Spencer Ripple, Phillip John Platt, Richard Allen White Jr and Stuart Edward Jr Woodcock.
View institutional ownership trends
.

How do I buy shares of Ingevity?

Shares of NGVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSE:NGVT) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -